Compare Commvault Systems Inc (CVLT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Merck & Co., Inc. — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.25B), while Merck & Co., Inc. trades at $142.44 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 56.2× Commvault Systems Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Merck & Co., Inc. for 98 Days on average.
| CVLT | MRK | |
|---|---|---|
Market Cap | $6.25B | $351.28B |
Volume | 632,727 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $176.52 | $156.43 |
52-Week Low | $75.18 | $82.49 |
Typical Hold Time | 17 Days | 98 Days |
Enterprise Value | $6.24B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 81.09% gross margins and 32.77% ROE. Recent business developments include achieving AWS Data Competency and expanding FedRAMP High authorized services, positioning the company for continued growth in the cybersecurity resilience market.
CVLT presents a compelling growth story with strong fundamentals and positive analyst sentiment, though elevated valuation ratios (P/E 96.73, P/B 120.15) suggest premium pricing. The primary investment opportunity lies in the company's leadership in AI-era resilience solutions, while risks include valuation sensitivity and competitive pressures in the enterprise software space. Wall Street maintains a bullish stance with 54.55% buy ratings and a $156.55 consensus price target.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
